

**IN THE CLAIMS**

Please amend the claims as follows:

1. (currently amended) A method for treating a vascular disorder in a mammal, which comprises administering to a mucosal surface of said mammal an effective amount of a composition comprising at least one agent selected from the group consisting of [[a]] an isolated HSP60/65 heat shock protein, a therapeutically effective fragment of [[a]] an isolated HSP60/65 heat shock protein, and a therapeutically effective peptide analog of [[a]] an isolated HSP60/65 heat shock protein, wherein the effective amount is sufficient to treat the disorder.
2. (original) The method of claim 1 wherein said mucosal surface comprises nasal epithelium.
3. (original) The method of claim 1 wherein said mucosal surface comprises oral mucosa.
4. (original) The method of claim 1 wherein said mucosal surface comprises a luminal surface of a gastrointestinal organ selected from the group consisting of: stomach, small intestine, large intestine, and rectum.
5. (original) The method of claim 1 wherein said disorder comprises a cell-mediated immune response.
6. (original) The method of claim 1 wherein said disorder comprises an antibody-mediated immune response.
7. (original) The method of claim 1 wherein said disorder is atherosclerosis.
8. (original) The method of claim 1 wherein said heat shock protein is HSP65.
9. (original) The method of claim 1 wherein said heat shock protein is human HSP60.

10. (original) The method of claim 1 wherein said heat shock protein is chlamydial HSP60.

11. (currently amended) A method for treating a vascular disorder in a mammal, which comprises administering to said mammal by inhalation an effective amount of a composition comprising at least one agent selected from the group consisting of [[a]] an isolated HSP60/65 heat shock protein, a therapeutically effective fragment of [[a]] an isolated HSP60/65 heat shock protein, and a therapeutically effective peptide analog of [[a]] an isolated HSP60/65 heat shock protein, wherein the effective amount is sufficient to treat the disorder.

12.-18. (canceled)

19. (currently amended) A method for suppressing a vascular disorder in a mammal, which comprises administering to said mammal via the pulmonary tract an effective amount of at least one agent selected from the group consisting of [[a]] an isolated HSP60/65 heat shock protein, a therapeutically effective fragment of [[a]] an isolated HSP60/65 heat shock protein, and a therapeutically effective peptide analog of [[a]] an isolated HSP60/65 heat shock protein, wherein the effective amount is sufficient to treat the disorder.

20.-24. (canceled)

25. (withdrawn) A method for suppressing a cell-mediated inflammatory disorder in a mammal, which comprises discharging into the pulmonary tract of said mammal an effective amount of a composition comprising at least one agent selected from the group consisting of a heat shock protein, a therapeutically effective fragment of a heat shock protein, and a therapeutically effective analog of a heat shock protein, wherein the effective amount is sufficient to treat the disorder.

26.-30. (canceled)

31. (currently amended) A method for treating a vascular disorder in a mammal, which comprises orally or enterally administering to said mammal an effective amount of a

composition comprising at least one agent selected from the group consisting of [[a]] an isolated HSP60/65 heat shock protein, a therapeutically effective fragment of [[a]] an isolated HSP60/65 heat shock protein, and a therapeutically effective peptide analog of [[a]] an isolated HSP60/65 heat shock protein, wherein the effective amount is sufficient to treat the disorder.

32.-43. (canceled)

44. (withdrawn) A composition for treating a vascular disorder in a mammal, which comprises administering at least one agent selected from the group consisting of a heat shock protein, a therapeutically effective fragment of a heat shock protein, and a therapeutically effective analog of a heat shock protein, wherein the effective amount is sufficient to treat the disorder.

45.-55. (canceled)